Hemogenyx Pharmaceuticals Corrects AGM Notice Error

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an update.

Hemogenyx Pharmaceuticals has announced a correction to its recent Notice of Annual General Meeting due to a clerical error in Resolutions 6 and 7, which pertain to the authority to allot shares and the disapplication of pre-emption rights. The error involved an incorrect number for the nominal value of shares, which was intended to represent 100% of the company’s issued share capital. This correction ensures the company can maintain strategic and operational flexibility, particularly in securing timely and efficient financing options necessary for its ongoing clinical trials. The AGM will proceed as scheduled, with the corrected resolutions aimed at supporting the company’s capital requirements and shareholder interests.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.

Average Trading Volume: 38,306

Technical Sentiment Signal: Sell

Current Market Cap: £7.43M

For an in-depth examination of HEMO stock, go to TipRanks’ Stock Analysis page.